Ignet

Gene Information

Gene symbol: NOV

Gene name: nephroblastoma overexpressed

HGNC ID: 7885

Synonyms: IGFBP9, CCN3

Related Genes

#	Gene Symbol	Number of hits
1	AGT	1 hits
2	CLU	1 hits
3	CTGF	1 hits
4	CYR61	1 hits
5	FOXO1	1 hits
6	GAS6	1 hits
7	IGFBP2	1 hits
8	IGFBP6	1 hits
9	IGFBP7	1 hits
10	INS	1 hits
11	PLXNA2	1 hits
12	WISP1	1 hits
13	WISP2	1 hits
14	WISP3	1 hits

Related Sentences

#	PMID	Sentence
1	1725860	Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6).
2	1725860	Six different insulin-like growth factor binding proteins (IGFBPs) have been identified by molecular cloning of their cDNAs from rat and human tissues and designated as IGFBP-1, -2, -3, -4, -5 and -6.
3	1725860	The total number of amino acid residues for the mature rat BPs ranges from 201 for IGFBP-6 to 270 for IGFBP-2, while the human homologs range from 216 for IGFBP-6 to 289 for IGFBP-2.
4	1725860	One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule.
5	1725860	An RGD sequence is found in the C-terminal of IGFBP-1 and -2.
6	8159583	[Distribution of new cases of insulin-dependent diabetes mellitus (IDDM) by age, sex, seasonality, and clinical characteristics at onset in youngsters from the Friuli Venezia Giulia region from 1987 to 1990].
7	8159583	A retrospective study was undertaken to estimate the incidence of insulin-dependent diabetes mellitus (IDDM) in youngs (< 18 years) in a North-East Province of Italy: Friuli Venezia Giulia (total population: 1,211,320; under age 18: 185,860).
8	8159583	All IDDM cases diagnosed between 1987 and 1990, with age onset < 18 years, and using insulin at discharge from hospital, were included. 73 new IDDM cases under 18 years (47 M, 26 F) were observed during the considered period.
9	8159583	First admission rates showed seasonal variations, with peaks in Oct/Nov and Jan/Feb.
10	12904165	The CCN family comprises cysteine-rich 61 (CYR61/CCN1), connective tIssue growth factor (CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), and Wnt-induced secreted proteins-1 (WISP-1/CCN4), -2 (WISP-2/CCN5) and -3 (WISP-3/CCN6).
11	18676994	Proteins related to cell growth (CYR61, protein NOV, and clusterin) were increased, whereas growth arrest-specific 6 (GAS6) and growth/differentiation factor 6 were decreased by Ang II stimulation.
12	18676994	Ang II-stimulated changes of plasminogen activator inhibitor-1, GAS6, cathepsin B, and periostin were validated by Western blot.
13	20195391	CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.
14	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
15	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
16	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
17	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
18	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
19	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
20	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
21	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
22	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
23	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
24	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
25	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
26	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
27	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
28	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
29	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
30	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
31	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
32	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
33	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
34	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
35	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
36	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
37	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
38	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
39	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
40	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
41	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
42	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
43	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
44	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
45	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
46	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
47	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
48	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
49	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
50	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
51	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
52	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
53	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
54	23705021	Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.
55	23705021	The forkhead transcription factor FoxO1 is a prominent mediator of insulin signaling in β-cells.
56	23705021	We reasoned that identification of FoxO1 target genes in β-cells could reveal mechanisms linking β-cell dysfunction to insulin resistance.
57	23705021	In this study, we report the characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in pancreatic β-cells.
58	23705021	FoxO1 binds to an evolutionarily conserved response element in the Ccn3 promoter to regulate its expression.
59	23705021	Accordingly, CCN3 levels are elevated in pancreatic islets of mice with overexpression of a constitutively active form of FoxO1 or insulin resistance.
60	23705021	Moreover, CCN3 decreases glucose oxidation, which translates into inhibition of glucose-stimulated Ca(2+) entry and insulin secretion.
61	23705021	Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.